Previous 10 | Next 10 |
Vaccitech (NASDAQ:VACC) has acquired privately-held Avidea Technologies giving it a platform capable of delivering multiple antigens and immunomodulators for immunotherapies. The $40M deal is comprised of $12.5M in cash and $27.5M in Vaccitech American Depository Shares, as well as devel...
Complementary technology platforms, expertise and capabilities provide unique synergistic opportunities. Exciting product candidates for oncology and autoimmunity based on the innovative SNAPvax TM platform, which has demonstrated unprecedented control over T cell in...
VTP-300, an immunotherapy candidate from Vaccitech (NASDAQ:VACC) for chronic hepatitis B, demonstrated reductions in surface antigen levels in an analysis of data from a phase 1a/2b study. "The new analysis showed that some patients on chronic antivirals receiving VTP-300 alone, as well as in...
Interim data from 27 patients, who had completed 3 months in the HBV002 study in chronic Hepatitis B (CHB) patients, demonstrated noted changes in surface antigen (HBsAg) levels, especially in the group receiving low-dose nivolumab with the heterologous boost (VTP-300). The HBV0...
Vaccine-development firms Vaccitech (NASDAQ:VACC) and Vaxxinity (NASDAQ:VAXX) sank to post-IPO lows Thursday as the biotech sector’s recent Omicron-related rally appears to have stalled. Vaxxinity (VAXX) – which is working on vaccines for COVID-19, Alzheimer’s Disease and...
OXFORD, United Kingdom, Nov. 24, 2021 (GLOBE NEWSWIRE) -- Vaccitech plc (NASDAQ: VACC), a clinical-stage biopharmaceutical company engaged in the discovery and development of novel immunotherapeutics and vaccines, today announced that Bill Enright, Chief Executive Officer, and Georgy Egorov...
Recent Acquisition of RNAi drug maker Dicerna by Novo Nordisk makes a case for eventual partnership/buyout of Arbutus Biopharma. AB-729 has proven to work in treating patients with Hepatitis B with significant Hepatitis B surface antigen reduction alone. Four triple combinations studi...
Novo Nordisk paid $3.3 billion to acquire RNAi drug maker Dicerna Pharmaceuticals. Acquisition of Dicerna makes sense from a business standpoint as Novo's strength lies in the metabolic disorder space, especially with key drugs like Ozempic, Wegovy and Saxenda. RNA interference is...
Vaccitech (NASDAQ:VACC): Q3 GAAP EPS of -$0.13 beats by $0.28. Revenue of $0.02M (-99.4% Y/Y) misses by $0.08M. Press Release For further details see: Vaccitech EPS beats by $0.28, misses on revenue
Interim data from two studies, HBV001 and HBV002, showed that in chronic Hepatitis B (CHB) patients the heterologous prime-boost vector combination, ChAdOx1-HBV + MVA-HBV (VTP-300), induced robust T cells against targeted hepatitis B viral antigens. ChAdOx-1-HBV alone (HBV001) w...
News, Short Squeeze, Breakout and More Instantly...
Vaccitech plc Company Name:
VACC Stock Symbol:
NASDAQ Market:
New Corporate Brand to be Unveiled at AASLD Liver Meeting® 2023 with Interim Data OXFORD, United Kingdom, Nov. 06, 2023 (GLOBE NEWSWIRE) -- Barinthus Biotherapeutics plc (NASDAQ: BRNS), formerly Vaccitech plc (NASDAQ: VACC), a clinical-stage biopharmaceutical company developing nov...
2023-09-27 06:52:40 ET DENVER, Colo., Sept 27, 2023 ( www.247marketnews.com )- The following stocks are the top performing U.S. stocks over the past week; Vaccitech (NASDAQ: VACC), Siyata Mobile (NASDAQ: SYTA), Soleno Therapeutics (NASDAQ: SLNO), Femasys (NASDAQ: FEMY), Immunovant (NASD...
2023-09-26 07:38:47 ET DENVER, Colo., Sept 26, 2023 ( www.247marketnews.com )- The following stocks are the top performing U.S. stocks over the past week; Vaccitech (NASDAQ:VACC), Lifezone Metals (NYSE:LZM), Globus Maritime Ltd. (NASDAQ:GLBS), Siyata Mobile (NASDAQ:SYTA), ESS Tech (NYSE...